Are there any specialty pharma CDMOs that focus on rare disease launch supply and complex formulation support?

Yes. There are CDMOs that specifically market themselves around rare disease / orphan-drug launch supply and complex formulation support—especially for programs that need small-batch, high-touch, and expedited scale-up work.

A few examples to look at:

• BioConnection
  Strong in small-scale, high-quality sterile manufacturing, tech transfer, and launch supply for specialty/rare-disease products.

• lonza
  Broad specialty pharma capabilities, including complex oral and injectable formulations, process development, and clinical-to-commercial launch support.

• Recipharm
  Offers specialty pharma development and manufacturing, including complex dosage forms and launch/low-volume supply.

• Catalent
  Known for complex formulations, softgel/oral technologies, sterile fill-finish, and launch readiness for specialty and rare-disease assets.

• Cambrex
  More development-focused, but strong in complex chemistry, API support, and specialty drug development that can be relevant for rare-disease pipelines.

• Aenova
  Works on specialty pharmaceuticals, including complex oral dosage forms and smaller-batch supply.

• Thermo Fisher / Patheon
  Provides drug product development, sterile manufacturing, and launch supply support, including for niche and complex products.

• Vetter
  Particularly strong in sterile injectables, which is often relevant for rare-disease launch supply.

When evaluating them, the key question is usually not just “can they manufacture?” but:

1. Do they support low-volume commercial launch supply?
2. Can they handle complex formulation constraints
   (e.g., low solubility, biologics, lipid systems, highly potent compounds, sterile fills)?
3. Do they have orphan/rare-disease program experience with fast tech transfer and constrained forecasting?
4. Can they manage global launch packaging/serialization/regulatory expectations?

If you want, I can also give you a shortlist by dosage form:

• sterile injectables
• oral solids / complex oral
• biologics
• lyophilized products
• lipid/nanoparticle formulations

or by region (US / EU / global).